Front. Aging Neurosci. Frontiers in Aging Neuroscience Front. Aging Neurosci. 1663-4365 Frontiers Media S.A. 10.3389/fnagi.2014.00313 Neuroscience Original Research Amyloid Beta1–42 and the Phoshorylated Tau Threonine 231 in Brains of Aged Cynomolgus Monkeys (Macaca fascicularis) Darusman Huda Shalahudin 1 2 * Gjedde Albert 3 4 5 6 Sajuthi Dondin 7 Schapiro Steven J. 1 8 Kalliokoski Otto 1 Kristianingrum Yuli P. 9 Handaryani Ekowati 10 Hau Jann 1 1Department of Experimental Medicine, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark 2Department of Anatomy, Physiology and Pharmacology, Faculty of Veterinary Medicine, Bogor Agricultural University, Bogor, Indonesia 3Department of Neuroscience and Pharmacology, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark 4Center for Functionally Integrative Neuroscience, University of Aarhus, Aarhus, Denmark 5Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, USA 6Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada 7Primate Research Center, Bogor Agricultural University, Bogor, Indonesia 8Department of Veterinary Sciences, The University of Texas MD Anderson Cancer Center, Bastrop, TX, USA 9Department of Pathology, Faculty of Veterinary Medicine, University of Gajah Mada, Yogyakarta, Indonesia 10Division of Pathology, Department of Clinic, Reproduction and Pathology, Faculty of Veterinary Medicine, Bogor Agricultural University, Bogor, Indonesia

Edited by: P. Hemachandra Reddy, Texas Tech University, USA

Reviewed by: Changiz Geula, Northwestern University, USA; Koteswara Rao Valasani, The University of Kansas, USA

 *Correspondence: Huda Shalahudin Darusman, Department of Experimental Medicine, Panum Institute, Building 16.1, Blegdamsvej 3B, Copenhagen DK 2200, Denmark e-mail: hudada@sund.ku.dk

This article was submitted to the journal Frontiers in Aging Neuroscience.

 10 11 2014 2014 6 313 23 05 2014 24 10 2014 Copyright © 2014 Darusman, Gjedde, Sajuthi, Schapiro, Kalliokoski, Kristianingrum, Handaryani and Hau. 2014

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Pathological hallmarks indicative of Alzheimer’s disease (AD), which are the plaques of amyloid beta1–42 and neurofibrillary tangles, were found in brain of aged cynomolgus monkey. The aim of this study was to investigate if aged monkeys exhibiting spatial memory impairment and levels of biomarkers indicative of AD, had brain lesions similar to human patients suffering from senile dementia. Generating immunohistochemistry technique to biomarkers of amyloid beta1–42 and the phosphorylated tau 231, our study assessed the amyloidopathy, such as indicative to the senile plaques and cerebral amyloid angiopathy, and the tauopathy, to possible neurofibrillary tangles. Six aged monkeys were selected based on their spatial memory performance and profile of biomarkers of AD, divided equally to affected aged subject – with Memory-affected and low amyloid level, and aged with higher performance in memory and amyloid, as the age-matched subjects. Using immunohistochemistry, plaques of amyloid beta1–42 were observed in two out of three brains of aged subjects with memory impairment and biomarkers indicative of AD. The cerebral amyloid angiopathy was observed in both aged monkey groups, and unlike in the human, the amyloids were found to deposit in the small veins and capillaries. In one of the affected individuals, phosphorylated tau was positively stained intracellularly of the neurons, indicating a possibility of an early stage of the formation of tangles. These findings add to the body of evidence of the utility of the aged cynomolgus monkeys as a spontaneous model for Alzheimer-related disease.

 degenerative disease immunohistochemistry senile plaques neurofibrillary tangles cerebral amyloid angiopathy Introduction

Tests for several behavioral tasks, developed within the human neuropsychological domain, have been successfully adapted for use with non-human primates (NHP), including delayed response tasks (DRT) (Amici et al., 2010) where delays of various lengths are imposed between the presentation of a stimulus and the desired response (Bartus and Dean, 2009; Lacreuse and Herndon, 2009; Rodriguez and Paule, 2009; Nagahara et al., 2010). This type of memory tests is appropriate in assessing Alzheimer’s disease (AD), and as well as other affected cognitive function such as executive function and divided attention (Johannsen et al., 1999; Giannakopoulos et al., 2007). As some of the earliest cerebral lesions in the AD progression are typically located in the hippocampus (Deiana et al., 2011), spatial memory tests are of particular interest.

Delayed response tasks performance in cynomolgus monkeys (Macaca fascicularis) has recently been described (Darusman et al., 2013a) demonstrating that old monkeys (more than 20 years of age) performed poorer than young (4–9 years) and middle aged (10–16 years) individuals. The DRT performance was correlated with the levels of the core biomarkers indicative of AD, especially the amyloid-beta1–42 (Aβ42) (Darusman et al., 2013b, 2014), where the DRT performance was positively correlated with concentrations of Aβ42. Structural magnetic resonance imaging (MRI) studies identified abnormalities, such as atrophy in hippocampus and morphological changes in the cortical areas in aged monkeys with poor memory and low Aβ42 levels (Darusman et al., 2014).

Earlier studies of brain sections from older cynomolgus monkey revealed pathological hallmarks indicative of AD (Nakamura et al., 1998), and based on the combined findings described above, the present study was carried out to investigate whether animals with poor DRT performance and circulating biomarkers levels indicative of senile dementia also exhibited brain lesions such as senile plaques (SP) of Aβ42 and tauopathy. In the human, the progression of cognitive decline and biomarkers levels reflect the AD pathological processes in the brain (Andreasen and Blennow, 2005; Perrin et al., 2009). Low levels of circulating Aβ42 and elevated total tau (t-tau) and phosphorylated tau (p-tau), are related with the development of SP and NFT, respectively (Brody et al., 2008; Blennow et al., 2010; Jack et al., 2010; Albert et al., 2011). In rhesus monkeys, the incidence, distribution, and chemical composition of the Aβ deposits in the brain of young and aged individuals have been described (Sani et al., 2003; Nishimura et al., 2012) with higher level of Aβ1–40 (Aβ40) than the Aβ42.

In the present study, we examined the presence of Aβ42 and the p-tau by immunohistochemistry analysis in brain sections of aged monkeys selected from a previous study (Darusman et al., 2013a,b), based on low total DRT and low levels of Aβ42 in cerebrospinal fluid (CSF) compared with aged monkeys with better memory performance and high CSF Aβ42 levels. The DRT were assessed by the short term memory test (STMT), long term memory test (LTMT), and memory load test (MLT).

 Materials and Methods Subjects

From previous studies, we selected aged subjects above 20 years old that met the requirements of low levels of Aβ42(<5000 pg/ml) and low DRT performance (<40%) for the memory-affected group (Darusman et al., 2013a,b). Aged subjects characterized by high-circulating Aβ42 and high DRT performance were selected for the age-matched control group. Subject age was determined from birth certificates for the animals born in captivity and from dental scaling (Swindler, 2002) and estimated year of born for animals born in the wild.

The subjects in this study (Table 1) were limited to old individuals that were destined for euthanasia due to progressive weight loss, paleness of the mucous membranes, reduced appetite, and/or general weakness. These criteria yielded three memory-affected monkeys (two females and one male), and three age-matched monkeys (one female and two males). Two young monkeys (one female and one male) were included to control for potential confounds associated with age.

The characteristics of the subjects.

Tattoo/sex/age group Total DRT (%) Biomarker (pg/ml)
 Reference Agea
Aβ42 t-tau pT231
C2538/female/young 68.09 655.10 301.60 2.36 Darusman et al. (2013a) 9
C0744/male/young 60.50 620.00 568.60 6.27 Darusman et al. (2013a) 7
10063/female/memory-affected 40.58 16.01 92.62 4.81 Darusman et al. (2013b) 30
T3311/male/memory-affected 40.00 368.36 319.46 4.19 Darusman et al. (2013a) 30b
I1112/female/memory-affected 34.34 164.96 219.85 5.45 Darusman et al. (2013a) 29
10749/female/age-matched 61.67 416.36 370.57 4.11 Darusman et al. (2013b) 30
9661/male/age-matched 60.16 480.76 277.71 7.55 Darusman et al. (2013b) 27
T3283/male/age-matched 66.42 524.65 60.64 4.37 Darusman et al. (2013b) 30b

Data are collected from the references Darusman et al. (2013a,b). DRT performance is presented as the collected percent of trials where the subject could correctly retrieve a hidden item following a predetermined delay. Biomarker levels were measured in serum and CSF.

aUp to the end of year of 2013.

bEstimated from the year of birth by a population survey in 1983.

All subjects were housed at the AAALAC-accredited Primate Research Center, Bogor Agricultural University (PRC, IPB) in pairs or social groups of various sizes. During the testing period, the subjects were individually housed indoors in adjacent cages, which permitted some tactile contact through perforated acrylic panels. The subjects’ housing conditions and test procedures were approved by the PRC IPB Animal Care and Use Committee. The subjects’ characteristics with their previous DRT performance and biomarker levels are presented in Table 1.

 Histopathology

The animals were euthanized with pentobarbital and phenytoin injections (Euthasol™, Virbac, Fort Worth, TX, USA) followed by intracardial sodium chloride 0.9% perfusions and exsanguination; the intracardial perfusion was continued with paraformaldehyde (4%). Brains were collected and immersed in 10% paraformaldehyde solution for 24 h. Subsequently, the brains were fixated in buffered formalin 10% (pH 7). Fixated brains were sectioned in the coronal plane allowing for analyses of five distinct regions: the frontal, occipital, parietal and temporal lobes, and the hippocampus.

All sections were embedded in paraffin wax and cut into 5 μm sections. Hematoxylin-eosin (HE) staining was applied for routine examination of the brain, especially for observing degeneration signs (apoptotic neuron signs such as chromatolysis, gliosis, vacuolization) because we were not applying immunohistochemistry studies of these degeneration signs. Congo-red staining was also applied to observe amyloid in general. For immunohistochemistry of Aβ42 and p-tau, sections were treated with sodium citrate buffer at 95°C for 30 min, and to minimize non-specific binding, sections were treated with 3% hydrogen peroxide in methanol for 30 min at room temperature, and blocked using 1% fetal bovine serum and 10% skimmed milk in PBS for 30 min at room temperature. An AD detection kit (Millipore™, Temecula, CA, USA) was used to identify Aβ42 and p-tau threonine 231 (pT231). The kit contained polyclonal antibodies against human Aβ42 (catalog number AB5078P) and pT231 (catalog number MAB3420SP).

The sections were incubated with the specific antibodies (diluted 1:500 in PBS) overnight at 4°C. After washing with PBS, the sections were incubated with a biotinylated secondary antibody for 30 min, and subsequently with Streptavidin-Horse Radish Peroxidase (HRP) for 30 min at room temperature (DAKO-LSAB+ system HRP kit; Glostrup, Denmark). Diaminobenzidine (DAB) was applied at room temperature until an appropriate intensity was obtained (2–5 min). Sections were rinsed in distilled water, counterstained with HE to visualize tissue morphology and then mounted with Entellan® (product number 1079610100, Merck KGaA, Darmstadt, Germany). Negative controls (without secondary antibody), antibody control (treated with normal rabbit serum), and photomicrograph control, were included. All slides (three slides for each brain region, times each staining procedure were analyzed for each subject; i.e., 3 × 5 × 7 = 105) were scored independently by two trained pathologists that were blinded to the identity of the individuals. Scores are summarized in Table 2.

Scoring criteria of the histopathology of the brain.

Score Degeneration Amyloid disorders
 Tauopathy
CAA Senile plaques
1 Condensed chromatin inside nuclei (chromatolysis) Deposit of amyloid in vascular wall of arterioles Diffused plaques – appearing as small numbers of nodules in the brain parenchyma p-tau detected inside the cytoplasm of the neuron (intracellular stage)
2 Aggregation of satellite cell/glial cell (gliosis) Deposit of amyloid in vascular wall of venules Compacted plaques – appearing in larger amounts and sizes in the brain parenchyma p-tau detected in the cytoplasm and/or axon of the neuron (fibrillar stage)
3 Formation of vacuole sites as indicative of active phagocytosis of the degenerated neuron (vacuolization) Deposit of amyloid in vascular wall of capillaries Compacted plaques in the brain parenchyma associated with degeneration of the surrounding nerve p-tau detected as tangled formations outside of the neuron (extracellular stage)

The degeneration score follows the progression of the apoptotic nerve cell (Kettemann et al., 2011). The degree of chromatolysis and the number of satellite cells or glial cells (Gliosis) was also incorporated in the degeneration score (Chen et al., 2013). Two aspects of amyloidopathy were scored: cerebral amyloid angiopathy (CAA) and SP (Heuer et al., 2012), where CAA scores were based on the localization of Aβ42 (Attems and Jellinger, 2004) and plaques were scored by morphology (lowest score was valued when the plaques appeared as small numbers and diffused, continued with compacted formation and compacted plaques with sign of degeneration surrounding as the highest score). The tauopathy was scored based on which stage the tangles formation was perceived to be in Augustinack et al. (2002).

 Results Degeneration

The histopathology findings (scores and the lobes where the lesion appeared) are presented in Table 3. Signs of brain degeneration were found in the aged monkeys, both the memory-affected and aged-matched subjects. Degeneration signs such as gliosis and vacuolization were present in the brains of all aged, but not in young animals. Early signs of degeneration were found in young animals, observed as a chromatolysis, while the later stages – the gliosis and vacuolization – were only observed in aged animals, both the memory-affected and age-matched subjects. These degeneration signs were observed in the frontal lobe of all the aged subjects (n = 6), in the parietal lobe of most (n = 5), and in the temporal and occipital lobes of some (n = 2). A degeneration of the hippocampus was found only in the memory-affected aged monkeys observed as chromatolysis.

Histopathology findings and summary of the scores.

Tattoo Group Average score from two observers (lobesa)
Degeneration CAA Senile plaques Tauopathy
C2538 Young 1(P) 0 0 0
C0744 Young 1(P) 0 0 0
10063 Memory-affected 2(F), 2(P), 1(O), 1(Hip) 3(F), 2(T) 0 0
T3311 Memory-affected 3(F), 2(T), 1(Hip) 3(F), 2(P), 1(O) 2(F), 1(P), 1(Hip) 0
I1112 Memory-affected 3(F), 2(T), 1(O), 1(P), 1 (Hip) 2(F), 2(T), 1(O), 1(P), 1 (Hip) 2(F), 1(T), 1(O), 1(Hip) 1 (T), 1 (O)
10749 Age-matched 3(F), 2(P) 2 (F), 2(T), 1(Hip) 0 0
9661 Age-matched 3 (F), 2 (P) 2 (F), 1(T), 1(P) 0 0
T3283 Age-matched 2(F), 2 (P), 1(O) 2(F), 2 (T), 1 (O) 0 0

aF, frontal lobe; T, temporal lobe; P, parietal lobe; O, Occipital lobe; Hip, hippocampus.

 CAA

The CAA was found in the small vessels of the brain in all of the aged monkeys. Brown coloration from DAB appeared in the vascular wall of the brain capillaries, preferentially in small veins (Figure 1). The CAA was observed in the blood vessels of the frontal lobe (n = 6), temporal lobes (n = 5), occipital and parietal lobes (each n = 3), and hippocampus (n = 2). The CAA was observed in the capillaries of the frontal lobe in the Memory-affected monkeys (n = 2).

(A) Brain section from the temporal lobe of a memory-affected animal (subject T3311) treated with a polyclonal serum against human Aβ42 and stained with DAB. The inset picture is a photomicrograph control treated with nonsense rabbit serum. (B) The occipital lobe of an Aged-matched subject (subject 10749); and (C) the hippocampus (subject I1112); arrows indicate deposition of the Aβ42 inside the walls of small veins. Scale bars: 60 μm.

 Senile plaques

Plaques of Aβ42 in the parenchyma were observed in the brain from two monkeys of the memory-affected group (Figure 2); subjects I1112 and T3311. The plaques were principally found in the frontal, temporal and parietal lobes, and the hippocampus. The compacted shape of the plaques was observed only in frontal lobes, while the diffused shapes were found in the other aforementioned lobes.

Brain section of the frontal lobe from a Memory-affected animal (subject I1112) demonstrating Aβ42 plaques in the parenchyma, (A) stained with HE, (B) Congo red and (C) with anti-Aβ42 antiserum/DAB, and (D) HE from Aged-matched subject (subject 10749). Arrows indicate Aβ42 plaques. Scale bars: 60 μm.

 Tauopathy

The pT231 was found in the temporal and occipital lobe from one subject belonging to the memory-affected group (I1112). The pT231-positive structures appeared only in the cytoplasm of the neuron cell (Figure 3). The brownish colorization from the pT231 antibody was weaker compared with the other DAB staining of the SP and CAA.

The occipital lobe of an age-matched subject (T3283) (A), the occipital lobe of a memory-affected subject (I1112) (B), and temporal lobe (C). Sections have been treated with a polyclonal serum against human p-tau pT231 and stained with DAB. Arrows indicate the presence of pT231 in the cytoplasm of nerve cells. Scale bars: 60 μm.

 Discussion

In addition to degenerative lesions, such as the microgliosis and vacuolization, we found the CAA in both aged groups and not in the young individuals – defined by an accumulation of amyloid beta in the brain vascular wall: cerebral beta-amyloid angiopathy (Rensink et al., 2003; Revesz et al., 2003, 2009; Greenberg et al., 2004). Since both aged groups developed the CAA, it suggested that the CAA may occur spontaneously in cynomolgus monkeys as in other aged NHP species, such as Rhesus monkeys (Walker, 1997; Heuer et al., 2012).

Qualitatively, the CAA in the memory-affected and aged-matched groups shared same relative amounts and similar to location in lobes where the lesions were present, namely the frontal and parietal-temporal lobes, which are the brain lobes related to memory function and also affected in AD and frontotemporal disease (FTD) in the human (Naggara et al., 2006; Rodriguez and Paule, 2009; Heuer et al., 2012), along with the hippocampus area (Johannsen et al., 2000; Deiana et al., 2011). CAA is present in almost in all cases of AD (Okamoto et al., 2009, 2012).

In humans, CAA is most prominent in the arterioles and less frequent in veins and capillaries (Preston et al., 2003), while interestingly our findings showed that amyloid beta deposits in the small veins and capillaries of the cynomolgus monkey. More thorough study of the mechanism of Aβ deposition in the veins is required in order to confirm whether or not the Aβ internalizes into endothelial cells, from blood passing through capillary pores, and thereby becomes detectable inside the vessel wall of veins and capillaries. The suspected CAA inside the capillaries and small veins correlates with AD pathology (Attems and Jellinger, 2004) and cognitive impairment (Eurelings et al., 2010). Our findings thus support studies of CAA in other aged old world monkeys (Walker, 1997; Nakamura et al., 1998; Oikawa et al., 2010).

In rhesus monkey and cynomolgus monkey, CAA and the parenchymal plaques of amyloid beta, are correlated (Nakamura et al., 1998; Levine and Walker, 2006) and our findings may support this. Our findings suggest that memory impaired cynomolgus monkeys suffer from an amyloid-related disease manifested as SP in the brain. On the other hand, animals with spontaneous amyloid-like disorder such as the dog with canine cognitive dysfunction had a fundamentally different relationship between the cognitive disorder and the retention of amyloid load sensitive marker Pittsburgh compound B (Fast et al., 2013).

Among three Memory-affected subjects, we found two subjects (I1112 and T3311) with the parenchymal form of amyloid beta inside the frontal, temporal lobes, and the hippocampus. The plaques were present in the same lobes where CAA was found. In the rhesus monkey, the deposits of Aβ were observed principally in the cortical, paralimbic, and core limbic cortical zones corresponding to mild, moderate, and heavy burden, respectively (Sani et al., 2003). Along with Nishimura et al. (2012), this study of rhesus monkeys also emphasizes the higher proportion of Aβ40 compared with the Aβ42. The absence of Aβ40 analysis in our study seems limit the whole interpretation.

However, another study in the species showed that the Aβ42 often predominate the Aβ40 in the cortical level of both temporal and occipital lobes, although the relative level of Aβ40 remain higher in the occipital cortex (Rosen et al., 2011). The additional immunohistochemistry of Aβ40 could add more information about the proportion of the Aβ in the cynomolgus monkey. This would support a biomarker study by Yue et al. (2014), which describes that Aβ42 was significantly associated with aging but not with the Aβ40 in cynomolgus monkey.

Similar to other studies (Oikawa et al., 2010; Heuer et al., 2012), we also found signs of both nerve damage and tangle formation in the brain of aged monkeys although the location of the plaques and the tangles were not correspondently the same. An old female from the memory-affected group (I1112), which had the parenchymal form of amyloid beta stained positively for pT231 in the body of nerve cells in the temporal and occipital lobes. In AD patients, this is the early stage of NFT, indicated by the intracellular form of NFT (Augustinack et al., 2002). The identified p-tau in the neuron’s cytoplasm was not corresponded with the SP, showed by the differences of the lobes’ location between SP and p-tau. This finding agrees with a previous study in cynomolgus monkey (Oikawa et al., 2010) that the pathological differences of SP and tauopathy in the species is specific and may differed with human’s AD pathology.

Although the present study was small, it adds to the body of evidence (Oikawa et al., 2010; Heuer et al., 2012) that support the neuropathology of the aged cynomolgus monkey as a potential model for studies of spontaneous disease of Alzheimer-type, especially the amyloid-related brain pathology and also suggests the potential for further study of p-tau mediated pathology in the species (Walker, 1997; Levine and Walker, 2006; Oikawa et al., 2010; Heuer et al., 2012). Future studies of high relevance would include more detailed analyses of the Aβ40, Aβ42, and the pT231 presence in each of the brain lobes to confirm the expression of both biomarkers and to complement the histopathology results.

 Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The authors thank the Director of the Primate Research Center IPB (Dr. Joko Pamungkas) and staff (Dr. Irma Suparto, Dr. Nengah Budiarsa, and Dr. Diah Pawitri), and the pathologist at the Primate Research Center (Dr. Sylvia A. Prabandari). This study was supported by the Directorate of Higher Education, Ministry of Education, and Republic of Indonesia through a PhD fellowship to Dr. Huda Shalahudin Darusman.

 References Albert M. S. De Kosky S. T. Dickson D. Dubois B. Feldman H. H. Fox N. C. (2011). The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7, 270–279.10.1016/j.jalz.2011.03.008 Amici F. Aureli F. Call J. (2010). Monkeys and apes: are their cognitive skills really so different? Am. J. Phys. Anthropol. 2010, 188–197.10.1002/ajpa.2130520853474 Andreasen N. Blennow K. (2005). CSF biomarkers for mild cognitive impairment and early Alzheimer’s disease. Clin. Neurol. Neurosur. 107, 165–173.10.1016/j.clineuro.2004.10.01115823670 Attems J. Jellinger K. A. (2004). Only cerebral capillary amyloid angiopathy correlates with Alzheimer pathology – a pilot study. Acta Neuropathol. 107, 83–90.10.1007/s00401-004-0866-714655019 Augustinack J. C. Schenider A. Mandelkow E. M. Hyman B. T. (2002). Specific tau phosphorylation sited correlate with severity of neuronal cytopathology in Alzheimer’s disease. Acta Neuropathol. 103, 26–35.10.1007/s00401010042311837744 Bartus R. T. Dean R. L. III (2009). Pharmaceutical treatment for cognitive deficits in Alzheimer’s disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps. Psychopharmacology 202, 15–36.10.1007/s00213-008-1365-719011839 Blennow K. Hampel H. Weiner M. Zetterberg H. (2010). Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6, 131–144.10.1038/nrneurol.2010.4 Brody D. L. Magnoni S. Schwetye K. E. Spinner M. L. Esparza T. J. Stocchetti N. (2008). Amyloid-β dynamics correlate with neurological status in the injured human brain. Science 321, 1221–1224.10.1126/science.116159118755980 Chen X. Errangi B. Li L. Glasser M. F. Westlye L. T. Fjell A. M. (2013). Brain aging in humans, chimpanzees (Pan troglodytes), and rhesus macaques (Macaca mulatta): magnetic resonance imaging studies of macro- and micro-structural changes. Neurobiol. Aging 10, 2248–2260.10.1016/j.neurobiolaging.2013.03.02823623601 Darusman H. S. Call J. Sajuthi D. Schapiro S. J. Gjedde A. Kaliokoski O. (2013a). Delayed response task performance as a function of age in cynomolgus monkeys (Macaca fascicularis). Primates 55, 259–267.10.1007/s10329-013-0397-8 Darusman H. S. Sajuthi D. Kalliokoski O. Jacobsen K. R. Call J. Schapiro S. J. (2013b). Correlations between serum levels of beta amyloid, cerebrospinal levels of tau and phospho tau, and delayed response tasks in young and aged cynomolgus monkeys (Macaca fascicularis). J. Med. Primatol. 42, 137–146.10.1111/jmp.1204423530983 Darusman H. S. Pandelaki J. Mulyadi R. Sajuthi D. Putri I. A. Kalliokoski O. H. (2014). Poor memory performance in aged cynomolgus monkeys with hippocampal atrophy, depletion of amyloid beta 1-42 and accumulation of tau proteins in cerebrospinal fluid. In vivo 28, 173–184.24632970 Deiana S. Platt B. Riedel G. (2011). The cholinergic system and spatial learning. Behav. Brain Res. 221, 389–411.10.1016/j.bbr.2010.11.03621108971 Eurelings L. S. Richard E. Carrano A. Eikelenboom P. van Gool W. A. Rozemuller A. J. (2010). Dysphoric capillary cerebral amyloid angiopathy mimicking Creutzfeldt-Jakob disease. J. Neurol. Sci. 295, 131–134.10.1016/j.jns.2010.04.02020537354 Fast R. Rodell A. Gjedde A. Mouridsen K. Alstrup A. K. Bjarkam C. R. (2013). PiB fails to map amyloid deposits in cerebral cortex of aged dogs with canine cognitive dysfunction. Front. Aging Neurosci. 5:1–11.10.3389/fnagi.2013.0009924416017 Giannakopoulos P. Gold G. Kövari E. von Gunten A. Imhof A. Bouras C. (2007). Assessing the cognitive impact of Alzheimer disease pathology and vascular burden in the aging brain: the Geneva experiences. Acta Neuropathol. 113, 1–12.10.1007/s00401-006-0144-y17036244 Greenberg S. M. Gurol M. E. Rosand J. Smith E. E. (2004). Amyloid angiopathy-related vascular cognitive impairment. Stroke 35, 2616–2619.10.1161/01.STR.0000143224.36527.4415459438 Heuer E. Rosen R. F. Cintron A. Walker L. C. (2012). Nonhuman primate models of Alzheimer-like cerebral proteopathy. Curr. Pharm. 18, 1159–1169.10.2174/13816121279931588522288403 Jack C. R. Jr. Knopman D. S. Jagust W. J. Shaw L. M. Aisen P. S. Weiner M. W. (2010). Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 9, 119–128.10.1016/S1474-4422(09)70299-620083042 Johannsen P. Jakobsen J. Bruhn P. Gjedde A. (1999). Cortical responses to sustained and divided attention in Alzheimer’s disease. Neuroimage 10, 269–281.10.1006/nimg.1999.047510458942 Johannsen P. Jakobsen J. Gjedde A. (2000). Statistical maps of cerebral blood flow deficits in Alzheimer’s disease. Eur. J. Neurol. 7, 385–392.10.1046/j.1468-1331.2000.00088.x Kettemann H. Hanisch U. K. Noda M. Verkhratsky A. (2011). Physiology of microglia. Physiol. Rev. 91, 461–553.10.1152/physrev.00011.2010 Lacreuse A. Herndon J. G. (2009). “Nonhuman primate models of cognitive aging,” in Animal Model of Human Cognitive Aging, eds Bizon J. L. Woods A. (Humana Press, Springer), 29–58. Levine H. Walker L. C. (2006). “Models of Alzheimer’s disease,” in Handbook of Models for Human Aging, ed. Michael Conn P. (New York: Academic press), 121–134. Nagahara A. H. Bernot T. Tuszynski M. H. (2010). Age related cognitive deficits in rhesus monkeys mirror human deficits on an automated test battery. Neurobiol. Aging 31, 1020–1031.10.1016/j.neurobiolaging.2008.07.00718760505 Naggara O. Oppenheim C. Rieu D. Raoux N. Rodrigo S. Dalla B. G. (2006). Diffusion tensor imaging in early Alzheimer’s disease. Acta Neuropathol. 82, 239–259.10.1016/j.pscychresns.2006.01.005 Nakamura S. Nakayama H. Goto N. Ono F. Sakakibara I. Yoshikawa Y. (1998). Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys. J. Med. Primatol. 27, 244–252.10.1111/j.1600-0684.1998.tb00244.x9926980 Nishimura M. Nakamura S. Kimura N. Liu L. Suzuki T. Tooyama I. (2012). Age-related modulation of ϒ-secretase activity in non-human primate brains. J. Neurochem. 123, 18–21.10.1111/j.1471-4159.2012.07884.x22817324 Oikawa N. Kimura N. Yanagisawa K. (2010). Alzheimer-type tau pathology in advanced old nonhuman primate brains harboring substantial amyloid deposition. Brain Res. 1315, 137–149.10.1016/j.brainres.2009.12.00520004650 Okamoto Y. Ihara M. Fujita Y. Ito H. Takahashi R. Tomimoto H. (2009). Cortical microinfarcts in Alzheimer’s disease and subcortical vascular dementia. Neuroreport 20, 990–996.10.1097/WNR.0b013e32832d2e6a Okamoto Y. Yamamoto T. Kalaria R. N. Senzaki H. Maki T. Hase Y. (2012). Cortical hypoperfusion accelerates cerebral amyloid angiopathy and promotes cortical microinfarcts. Acta Neuropathol. 123, 381–394.10.1007/s00401-011-0925-922170742 Perrin R. Fagan A. M. Holtzman D. M. (2009). Multimodal techniques for diagnosis and prognosis of Alzheimer’s disease. Nature 461, 916–922.10.1038/nature0853819829371 Preston S. D. Steart P. V. Wilkinson A. Nicoll J. A. Weller R. O. (2003). Capillary and arterial cerebral amyloid angiopathy in Alzheimer’s disease: defining the perivascular route for the elimination of amyloid beta from the human brain. Neuropathol. Appl. Neurobiol. 29, 106–117.10.1046/j.1365-2990.2003.00424.x12662319 Rensink A. A. de Waal R. M. Kremer B. Verbeek M. M. (2003). Pathogenesis of cerebral amyloid angiopathy. Brain Res. Brain Res. Rev. 43, 207–223.10.1016/j.brainresrev.2003.08.001 Revesz T. Ghiso J. Lashley T. Plant G. Rostagno A. Frangione B. (2003). Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J. Neuropathol. Exp. Neurol. 62, 885–898.14533778 Revesz T. Holton J. L. Lashley T. Plant G. Frangione B. Rostagno A. (2009). Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. Acta Neuropathol. 118, 115–130.10.1007/s00401-009-0501-819225789 Rodriguez J. S. Paule M. G. (2009). “Working memory delayed response tasks in monkeys,” in Methods of Behavior Analysis in Neuroscience, 2nd Edn, ed. Buccafusco J. J. (Boca Raton, FL: CRC Press), 247–266. Rosen R. F. Walker L. C. Levine H. (2011). PIB binding in aged primate brain: enrichment of high affinity sites in human with Alzheimer’s disease. Neurobiol. Aging 32, 223–234.10.1016/j.neurobiolaging.2009.02.01119329226 Sani S. Traul D. Klink A. Niaraki N. Gonzalo-Ruiz A. Wu C. K. (2003). Distribution, progression and chemical composition of cortical amyloid-beta deposits in aged rhesus monkeys: similarities to the human. Acta Neuropathol. 105, 145–156.12536225 Swindler D. R. (2002). Primate Dentistry: an Introduction to the Teeth of Non-Human Primates. Cambridge: Cambridge University Press. Walker L. C. (1997). Animal models of cerebral β-amyloid angiopathy. Brain Res. Rev. 25, 70–84.10.1016/S0165-0173(97)00017-9 Yue F. Lu C. Ai Y. Chan P. Zhang Z. (2014). Age-associated changes of cerebrospinal fluid amyloid-β and tau in cynomolgus monkeys. Neurobiol. Aging 35, 1656–1659.10.1016/j.neurobiolaging.2014.01.13924581480